Is KDNY or RYLD a better dividend investment in 2026?

KDNY currently yields 4.95% with a 5% 5-year dividend growth rate. RYLD yields 12.14% with 5% growth. The better choice depends on your goal: RYLD offers higher current income.

What is the dividend yield difference between KDNY and RYLD?

KDNY has a forward dividend yield of 4.95% ($2.00/share annually). RYLD yields 12.14% ($1.81/share annually). The yield gap is 7.19 percentage points.

Home › Compare › KDNY vs RYLD

KDNY vs RYLD: Dividend Comparison 2026

KDNY yields 4.95% · RYLD yields 12.14%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 RYLD wins by $16.8K in total portfolio value

INVESTMENT

TIME HORIZON10 years

KDNY

● Live price

4.95%

Share price

$40.39

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$27.7K

Annual income

$679.74

Full KDNY calculator →

RYLD

● Live price

12.14%

Share price

$14.95

Annual div

$1.81

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$44.5K

Annual income

$2,587.35

Full RYLD calculator →

Portfolio growth — KDNY vs RYLD

📍 RYLD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	KDNY	RYLD
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, KDNY + RYLD cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

KDNY pays

RYLD pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

KDNY

Annual income on $10K today (after 15% tax)

$420.90/yr

After 10yr DRIP, annual income (after tax)

$577.78/yr

RYLD

Annual income on $10K today (after 15% tax)

$1,031.60/yr

After 10yr DRIP, annual income (after tax)

$2,199.25/yr

At 15% tax rate, RYLD beats the other by $1,621.47/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of KDNY + RYLD for your $10,000?

KDNY: 50%RYLD: 50%

100% RYLD50/50100% KDNY

Portfolio after 10yr

$36.1K

Annual income

$1,633.54/yr

Blended yield

4.52%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on KDNY right now

KDNY

Analyst Ratings

Buy

Hold

Consensus: Hold

Price Target

$30.00

-25.7% upside vs current

Range: $30.00 — $30.00

Altman Z

9.7

Piotroski

3/9

RYLD

No analyst data

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

KDNY buys

RYLD buys

No recent congressional trades found for KDNY or RYLD in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricKDNYRYLD

Forward yield	4.95%	12.14% ✓
Annual dividend / share	$2.00 ✓	$1.81
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$27.7K	$44.5K ✓
Annual income after 10y	$679.74	$2,587.35 ✓
Total dividends collected	$5.9K	$18.8K ✓
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: KDNY vs RYLD ($10,000, DRIP)

Year	KDNY Portfolio	KDNY Income/yr	RYLD Portfolio	RYLD Income/yr	Gap
1← crossover	$11,195	$495.17	$11,914	$1,213.65	$719.00 → RYLD
2	$12,497	$518.09	$14,099	$1,351.30	$1.6K → RYLD
3	$13,912	$540.49	$16,580	$1,494.55	$2.7K → RYLD
4	$15,448	$562.34	$19,384	$1,642.61	$3.9K → RYLD
5	$17,113	$583.59	$22,535	$1,794.70	$5.4K → RYLD
6	$18,915	$604.19	$26,063	$1,950.00	$7.1K → RYLD
7	$20,864	$624.12	$29,995	$2,107.69	$9.1K → RYLD
8	$22,968	$643.37	$34,361	$2,266.99	$11.4K → RYLD
9	$25,237	$661.91	$39,194	$2,427.12	$14.0K → RYLD
10	$27,684	$679.74	$44,525	$2,587.35	$16.8K → RYLD

KDNY vs RYLD: Complete Analysis 2026

KDNY — Stock

Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington.

Full KDNY Calculator →

RYLD — ETF

The Global X Russell 2000 Covered Call ETF (RYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Russell 2000 BuyWrite Index.

Full RYLD Calculator →

📬

Get this KDNY vs RYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

KDNY vs SCHD KDNY vs JEPI KDNY vs O KDNY vs KO KDNY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.